

Marina Berenguer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2034239/publications.pdf>

Version: 2024-02-01

226
papers

13,374
citations

29994

54
h-index

23472

111
g-index

253
all docs

253
docs citations

253
times ranked

9398
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018, 69, 461-511.	1.8	1,489
2	HCV-related fibrosis progression following liver transplantation: increase in recent years. <i>Journal of Hepatology</i> , 2000, 32, 673-684.	1.8	723
3	EASL recommendations on treatment of hepatitis C: Final update of the series†. <i>Journal of Hepatology</i> , 2020, 73, 1170-1218.	1.8	671
4	Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. <i>Hepatology</i> , 2002, 36, 202-210.	3.6	566
5	Natural History of Clinically Compensated Hepatitis C Virus-Related Graft Cirrhosis After Liver Transplantation. <i>Hepatology</i> , 2000, 32, 852-858.	3.6	505
6	High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. <i>Hepatology</i> , 1999, 29, 250-256.	3.6	504
7	Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5692-5697.	3.3	401
8	Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. <i>Journal of Hepatology</i> , 2008, 49, 274-287.	1.8	325
9	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016, 65, 524-531.	1.8	298
10	Hepatitis C and liver transplantation. <i>Journal of Hepatology</i> , 2001, 35, 666-678.	1.8	277
11	Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 679-687.	2.6	269
12	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet, The</i> , 2015, 385, 2502-2509.	6.3	245
13	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	1.3	239
14	Natural history of recurrent hepatitis C. <i>Liver Transplantation</i> , 2002, 8, S14-S18.	1.3	224
15	Contribution of obesity to hepatitis C-related fibrosis progression. <i>American Journal of Gastroenterology</i> , 2002, 97, 2408-2414.	0.2	203
16	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003, 38, 34-41.	3.6	190
17	De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. <i>Liver Transplantation</i> , 2001, 7, 51-58.	1.3	181
18	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 727-743.	0.5	178

#	ARTICLE	IF	CITATIONS
19	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. <i>Journal of Hepatology</i> , 2006, 44, 717-722.	1.8	170
20	Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. <i>Journal of Hepatology</i> , 1998, 28, 756-763.	1.8	163
21	Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. <i>Liver Transplantation</i> , 2007, 13, 21-29.	1.3	155
22	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2006, 12, 1067-1076.	1.3	154
23	What determines the natural history of recurrent hepatitis C after liver transplantation?. <i>Journal of Hepatology</i> , 2005, 42, 448-456.	1.8	148
24	Reversion of disease manifestations after HCV eradication. <i>Journal of Hepatology</i> , 2016, 65, S95-S108.	1.8	143
25	Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment. <i>Journal of Hepatology</i> , 2013, 58, 1028-1041.	1.8	132
26	De Novo Internal Neoplasms after Liver Transplantation: Increased Risk and Aggressive Behavior in Recent Years?. <i>American Journal of Transplantation</i> , 2004, 4, 596-604.	2.6	123
27	Treating hepatitis C infection in liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, 1192-1204.	1.3	123
28	Are posttransplantation protocol liver biopsies useful in the long term?. <i>Liver Transplantation</i> , 2001, 7, 790-796.	1.3	122
29	Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers. <i>Liver Transplantation</i> , 2007, 13, 1401-1404.	1.3	106
30	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	3.6	105
31	Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. <i>Liver Transplantation</i> , 2003, 9, 228-235.	1.3	104
32	Post-liver transplantation medical complications. <i>Annals of Hepatology</i> , 2006, 5, 77-85.	0.6	103
33	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2008, 14, 1449-1460.	1.3	101
34	Equally Interchangeable? How Sex and Gender Affect Transplantation. <i>Transplantation</i> , 2019, 103, 1094-1110.	0.5	101
35	Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. <i>Journal of Hepatology</i> , 2011, 55, 207-217.	1.8	97
36	Host and donor risk factors before and after liver transplantation that impact HCV recurrence. <i>Liver Transplantation</i> , 2003, 9, S44-S47.	1.3	90

#	ARTICLE	IF	CITATIONS
37	Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 820-827.	1.8	89
38	Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. <i>Hepatology</i> , 1999, 30, 1513-1520.	3.6	84
39	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, 762-767.	1.3	81
40	Outcomes in liver transplantation: Does sex matter?. <i>Journal of Hepatology</i> , 2015, 62, 946-955.	1.8	79
41	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	0.5	76
42	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. <i>Science Translational Medicine</i> , 2014, 6, 242ra81.	5.8	74
43	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	2.6	72
44	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	1.8	71
45	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
46	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Transplantation</i> , 2019, 103, 45-56.	0.5	69
47	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 738-746.	1.3	65
48	Liver Transplantation for Alcoholic Liver Disease. <i>Transplantation</i> , 2016, 100, 981-987.	0.5	65
49	Treatment of chronic hepatitis C in hemodialysis patients. <i>Hepatology</i> , 2008, 48, 1690-1699.	3.6	64
50	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. <i>Liver Transplantation</i> , 2005, 11, 456-462.	1.3	63
51	Effect of Calcineurin Inhibitors in the Outcome of Liver Transplantation in Hepatitis C Virus-Positive Recipients. <i>Transplantation</i> , 2010, 90, 1204-1209.	0.5	62
52	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 79-87.	1.3	60
53	Liver transplantation and hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 805-812.	0.7	59
54	Immunosuppression in liver transplant. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101681.	1.0	59

#	ARTICLE	IF	CITATIONS
55	Delisting <sc>HCV</sc>â€infectd liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , 2018, 38, 2170-2177.	1.9	54
56	Long-term outcome of â€long-term liver transplant survivorsâ€™™. <i>Transplant International</i> , 2013, 26, 740-750.	0.8	53
57	COVID-19 and liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 526-528.	8.2	53
58	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	1.8	49
59	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1255-1261.	0.8	48
60	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. <i>Liver Transplantation</i> , 2002, 8, 1020-1027.	1.3	47
61	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern?. <i>Liver Transplantation</i> , 2003, 9, 1152-1158.	1.3	47
62	Risk of extended criteria donors in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2008, 14, S45-S50.	1.3	46
63	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	0.5	44
64	Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy. <i>Journal of Hepatology</i> , 2012, 56, 1310-1316.	1.8	42
65	Combined resistance and endurance training at a moderateâ€toâ€high intensity improves physical condition and quality of life in liver transplant patients. <i>Liver Transplantation</i> , 2017, 23, 1273-1281.	1.3	42
66	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1143-1149.	0.5	41
67	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. <i>Liver Transplantation</i> , 2015, 21, 812-822.	1.3	39
68	Recurrence of hepatitis C after liver transplantation. <i>Annals of Gastroenterology</i> , 2013, 26, 304-313.	0.4	38
69	Recurrent hepatitis C genotype 1b following liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1207-1212.	0.8	37
70	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	1.8	35
71	Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2013, 95, 1148-1153.	0.5	35
72	Should organs from hepatitis Câ€positive donors be used in hepatitis Câ€negative recipients for liver transplantation?. <i>Liver Transplantation</i> , 2018, 24, 831-840.	1.3	34

#	ARTICLE	IF	CITATIONS
73	Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. <i>Transplantation</i> , 2011, 92, 334-340.	0.5	34
74	Treatment of Hepatitis C after Liver Transplantation. <i>Clinics in Liver Disease</i> , 2005, 9, 579-600.	1.0	33
75	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. <i>Journal of Clinical Virology</i> , 2018, 102, 77-83.	1.6	33
76	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
77	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008, 48, S93.	1.8	32
78	Recurrent hepatitis C: Worse outcomes established, interventions still inadequate. <i>Liver Transplantation</i> , 2007, 13, 641-643.	1.3	31
79	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. <i>Liver Transplantation</i> , 2014, 20, 25-34.	1.3	31
80	Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1671-1682.	2.6	31
81	Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. <i>Hemodialysis International</i> , 2018, 22, S8-S21.	0.4	29
82	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2020, 26, 866-877.	1.3	25
83	Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals. <i>Hepatology</i> , 2022, 75, 550-566.	3.6	25
84	Eliminaci3n de la hepatitis C. Documento de posicionamiento de la Asociaci3n Espa±ola para el Estudio del H4gado (AEEH). <i>Gastroenterolog4a Y Hepatolog4a</i> , 2019, 42, 579-592.	0.2	25
85	Management of Hepatitis C Virus in the Transplant Patient. <i>Clinics in Liver Disease</i> , 2007, 11, 355-376.	1.0	24
86	Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. <i>Liver Transplantation</i> , 2009, 15, 1709-1717.	1.3	24
87	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2819-2821.	2.4	24
88	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. <i>Transplantation</i> , 2020, 104, 2078-2086.	0.5	24
89	Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. <i>Current Opinion in Organ Transplantation</i> , 2005, 10, 81-89.	0.8	22
90	Stretching the boundaries for liver transplant in the 21st century. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 803-811.	3.7	22

#	ARTICLE	IF	CITATIONS
91	Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain. <i>Clinical Genetics</i> , 2020, 97, 758-763.	1.0	22
92	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , 2022, 76, 364-370.	1.8	22
93	Control of Blood Pressure in Liver Transplant Recipients. <i>Transplantation</i> , 2012, 93, 1031-1037.	0.5	21
94	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 1798-1807.	1.3	20
95	Impact of hepatitis C virus (<sc>HCV</sc>) antiviral treatment on the need for liver transplantation (<sc>LT</sc>). <i>Liver International</i> , 2018, 38, 1022-1027.	1.9	20
96	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019, 171, 496.	2.0	20
97	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004, 10, 217-227.	1.3	19
98	Hot topic in hepatitis C virus research: The type of immunosuppression does not matter. <i>Liver Transplantation</i> , 2011, 17, S24-S28.	1.3	19
99	Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , 2012, 32, 712-731.	1.9	19
100	Computational models of liver fibrosis progression for hepatitis C virus chronic infection. <i>BMC Bioinformatics</i> , 2014, 15, S5.	1.2	19
101	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis. <i>Transplantation</i> , 2017, 101, 916-923.	0.5	19
102	Fat and liver transplantation: clinical implications. <i>Transplant International</i> , 2018, 31, 828-837.	0.8	19
103	Non-Markov Multistate Modeling Using Time-Varying Covariates, with Application to Progression of Liver Fibrosis due to Hepatitis C Following Liver Transplant. <i>International Journal of Biostatistics</i> , 2010, 6, Article 7.	0.4	18
104	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. <i>Liver Transplantation</i> , 2013, 19, 69-77.	1.3	18
105	Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364-1365.	0.2	18
106	Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. <i>Journal of Hepatology</i> , 2018, 69, 966-968.	1.8	18
107	Hepatic steatosis and steatohepatitis: a functional meta-analysis of sex-based differences in transcriptomic studies. <i>Biology of Sex Differences</i> , 2021, 12, 29.	1.8	18
108	Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. <i>Annals of Hepatology</i> , 2019, 18, 855-861.	0.6	17

#	ARTICLE	IF	CITATIONS
109	Wilson's Disease: Facing the Challenge of Diagnosing a Rare Disease. <i>Biomedicines</i> , 2021, 9, 1100.	1.4	17
110	Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry. <i>Transplantation</i> , 2021, 105, 2255-2262.	0.5	17
111	Response to different therapeutic approaches in Wilson disease. A long-term follow up study. <i>Annals of Hepatology</i> , 2012, 11, 907-914.	0.6	15
112	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , 2015, 35, 2358-2362.	1.9	15
113	Controlling Diabetes After Liver Transplantation. <i>Transplantation</i> , 2016, 100, e66-e73.	0.5	15
114	Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología y Hepatología</i> , 2018, 41, 597-608.	0.2	15
115	O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study. <i>Journal of Hepatology</i> , 2015, 62, S191-S192.	1.8	14
116	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2022, 22, 626-633.	2.6	14
117	Are HCV-infected individuals candidates for hepatitis A vaccine?. <i>Lancet, The</i> , 1998, 351, 924-925.	6.3	13
118	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. <i>Clinics in Liver Disease</i> , 2003, 7, 631-650.	1.0	13
119	Treatment of recurrence of hepatitis B in transplant patients. <i>Journal of Hepatology</i> , 2003, 39, 190-193.	1.8	13
120	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. <i>Liver Transplantation</i> , 2011, 17, 1318-1327.	1.3	13
121	An objective definition for clinical suspicion of T cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017, 31, e13005.	0.8	13
122	Mortality and Causes of Death After Liver Transplantation: Analysis of Sex Differences in a Large Nationwide Cohort. <i>Transplant International</i> , 0, 35, .	0.8	13
123	Indications for and Results of Liver Retransplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1016-1017.	0.3	12
124	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. <i>Annals of Hepatology</i> , 2013, 12, 274-281.	0.6	12
125	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2016, 22, 4547.	1.4	12
126	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020, 104, 2087-2096.	0.5	12

#	ARTICLE	IF	CITATIONS
127	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.1	12
128	Live donor liver transplantation for hepatitis C: New data, old story. <i>Liver Transplantation</i> , 2006, 12, 516-519.	1.3	11
129	Antiviral therapy in patients with HCV-cirrhosis. <i>Annals of Hepatology</i> , 2009, 8, 292-297.	0.6	11
130	Cirrosis por hepatitis C. Estado actual. <i>Medicina Clínica</i> , 2017, 148, 78-85.	0.3	11
131	The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. <i>Transplantation</i> , 2019, 103, 19-21.	0.5	11
132	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. <i>PLoS ONE</i> , 2020, 15, e0228351.	1.1	11
133	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase III SATURN study. <i>Transplant Infectious Disease</i> , 2017, 19, e12696.	0.7	10
134	Pushing the donor limits: Deceased donor liver transplantation using organs from octogenarian donors. <i>Liver Transplantation</i> , 2017, 23, S22-S26.	1.3	10
135	Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: Can we avoid liver biopsies?. <i>Digestive and Liver Disease</i> , 2009, 41, 226-228.	0.4	9
136	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. <i>Annals of Hepatology</i> , 2013, 12, 974-978.	0.6	9
137	Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain. <i>World Journal of Hepatology</i> , 2020, 12, 277-287.	0.8	9
138	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	1.9	9
139	The New Era of Hepatitis C. <i>Clinics in Liver Disease</i> , 2017, 21, 421-434.	1.0	8
140	Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment. <i>Transplantation</i> , 2018, 102, e74-e81.	0.5	8
141	Frailty and Sarcopenia in Acute-to-Chronic Liver Failure. <i>Hepatology Communications</i> , 2021, 5, 1333-1347.	2.0	8
142	Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications. <i>Journal of Hepatology</i> , 2011, 55, 270-272.	1.8	7
143	Hepatitis C virus viral kinetics during 1±-2a or 1±-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimens. <i>Journal of Clinical Virology</i> , 2012, 53, 231-238.	1.6	7
144	Hepatitis C Virus-Associated Cholestatic Hepatitis: We Cannot Seem to Agree on Diagnostic Criteria. <i>Liver Transplantation</i> , 2013, 19, 115-117.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 123-128.	1.1	7
146	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. <i>Transplant International</i> , 2018, 31, 649-657.	0.8	7
147	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 328-349.	0.0	7
148	Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT-450/R/Ombitasvir, Dasabuvir and Ribavirin. <i>American Journal of Gastroenterology</i> , 2014, 109, S132.	0.2	6
149	Management of HCV in the liver transplant setting. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S115-S119.	0.7	6
150	Acute cellular rejection versus recurrent hepatitis <sc>C</sc> after liver transplantation: Clinical and pathological features driving a rational diagnostic approach. <i>Hepatology Research</i> , 2015, 45, 423-431.	1.8	6
151	Ciclosporin versus tacrolimus for HCV transplant recipients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 422-424.	8.2	5
152	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. <i>Future Microbiology</i> , 2015, 10, 1759-1766.	1.0	5
153	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , 2018, 18, 2409-2416.	2.6	5
154	Hepatitis C-related cirrhosis. Current status. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 78-85.	0.1	4
155	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. <i>Cellular Immunology</i> , 2022, 371, 104455.	1.4	4
156	Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?. <i>Transplantation</i> , 2022, 106, 2122-2136.	0.5	4
157	Viral hepatitis after liver transplantation. <i>Hepatology Research</i> , 2007, 37, S279-S286.	1.8	3
158	Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle. <i>Liver Transplantation</i> , 2012, 18, 755-760.	1.3	3
159	Beyond cure. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 355-360.	1.5	3
160	Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study. <i>Journal of Hepatology</i> , 2017, 66, S39-S40.	1.8	3
161	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.1	3
162	Posttransplant Calcineurin Inhibitors Levels and Inpatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. <i>Transplantation</i> , 2020, 104, 1201-1209.	0.5	3

#	ARTICLE	IF	CITATIONS
163	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016, 15, 512-23.	0.6	3
164	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Hepatology</i> , 2010, 52, S43.	1.8	2
165	New developments in the management of hepatitis C virus infection: focus on boceprevir. <i>Biologics: Targets and Therapy</i> , 2012, 6, 249.	3.0	2
166	Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, S403-S404.	1.8	2
167	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virusâ€œCoinfected Patients. <i>Liver Transplantation</i> , 2018, 24, 1476-1480.	1.3	2
168	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2019, 42, 579-592.	0.0	2
169	Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion. <i>Clinical Transplantation</i> , 2019, 33, e13629.	0.8	2
170	Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation. <i>Transplantation Direct</i> , 2019, 5, e487.	0.8	2
171	The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way. <i>Transplantation</i> , 2022, 106, e1-e2.	0.5	2
172	Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 599-607.	0.8	1
173	Optimum minimization strategies in hepatitis C virus infected liver transplant. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 641-646.	0.8	1
174	[137] RESPONSE TO PEGYLATED INTERFERON-RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR MIXED (ALCOHOL-HCV) CIRRHOSIS. <i>Journal of Hepatology</i> , 2007, 46, S62.	1.8	1
175	An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!. <i>Liver Transplantation</i> , 2010, 16, 697-700.	1.3	1
176	24 HIGHER SUSTAINED VIROLOGIC RESPONSE AND HISTOLOGIC IMPROVEMENT IN RECURRENT HEPATITIS C AFTER PEGYLATED INTERFERON PLUS RIBAVIRIN THERAPY UNDER CYCLOSPORINE-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSIVE THERAPY. <i>Journal of Hepatology</i> , 2010, 52, S11.	1.8	1
177	451 NO IMPACT OF OBESITY ON POST-LIVER TRANSPLANTATION OUTCOME AMONG HCV-INFECTED LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2010, 52, S183.	1.8	1
178	Reply to: â€œRenal impairment and anemia during triple therapyâ€œ. <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	1.8	1
179	P1207 TRIPLE THERAPY FOR HCV CIRRHOSIS IN LIVER TRANSPLANT CANDIDATES. HIGH RATE OF PREVENTION OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT) IN WELL SELECTED PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S490.	1.8	1
180	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Impact of Direct Anti-Viral Agents on Inactivation/De-Listing of Liver Transplant Candidates Listed for Decompensated C Cirrhosis: A European Study. <i>Journal of Hepatology</i> , 2016, 64, S153.	1.8	1
182	Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice. <i>Journal of Hepatology</i> , 2016, 64, S779.	1.8	1
183	Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus "positive donors. <i>Liver Transplantation</i> , 2016, 22, 47-51.	1.3	1
184	Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3 & 6). <i>Journal of Hepatology</i> , 2017, 66, S529-S530.	1.8	1
185	Pregnancy and autoimmune hepatitis: presentation and outcomes. <i>Journal of Hepatology</i> , 2018, 68, S233.	1.8	1
186	Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: another player in the game. <i>Transplant International</i> , 2018, 31, 972-974.	0.8	1
187	Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives. <i>BioMed Research International</i> , 2019, 2019, 1-2.	0.9	1
188	Características e impacto del sexo en una cohorte de pacientes con colangitis esclerosante primaria: experiencia de un centro trasplantador de la cuenca mediterránea. <i>Gastroenterología Y Hepatología</i> , 2021, , .	0.2	1
189	Circulating MicroRNAs. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	1
190	Recurrence of Hepatitis C After Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 3311-3312.	0.3	0
191	DE NOVO MALIGNANCIES AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 2008, 86, 665.	0.5	0
192	Reply:. <i>Hepatology</i> , 2009, 49, 2126-2126.	3.6	0
193	Management of Hepatitis C in Patients with End-stage Renal Disease. <i>Current Hepatitis Reports</i> , 2010, 9, 38-46.	0.3	0
194	1138 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI): FOLLOW-UP IN A COHORT OF PATIENTS IDENTIFIED IN 24 TERTIARY CARE CENTRES IN SPAIN. <i>Journal of Hepatology</i> , 2010, 52, S440.	1.8	0
195	450 LOW EFFICACY OF ANTIVIRAL THERAPY IN HCV-LIVER TRANSPLANT RECIPIENTS TREATED AT ADVANCED STAGES OF FIBROSIS. <i>Journal of Hepatology</i> , 2010, 52, S183.	1.8	0
196	490 IMPACT OF OBESITY ON SURVIVAL IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2010, 52, S198.	1.8	0
197	Treatment of hepatitis C in the post-transplant setting. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 26-29.	0.2	0
198	517 POST-LIVER TRANSPLANTATION (LT) OUTCOME IN HIV/HCV CO-INFECTED PATIENTS. COMPARISON WITH MONOINFECTED PATIENTS WITH HCV-CIRRHOSIS. <i>Journal of Hepatology</i> , 2011, 54, S212.	1.8	0

#	ARTICLE	IF	CITATIONS
199	521 PATIENTS SURVIVING AT LEAST 10 YEARS POST LIVER TRANSPLANTATION: LONG TERM COMPLICATIONS. Journal of Hepatology, 2011, 54, S213-S214.	1.8	0
200	540 VALIDATION OF A PREDICTIVE MODEL FOR CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION. Journal of Hepatology, 2011, 54, S221.	1.8	0
201	806 TRIPHASIC VIRAL LOAD KINETICS OF HEPATITIS C VIRUS DURING ANTIVIRAL THERAPY POST-TRANSPLANTATION: EFFECT OF THE TYPE OF PEGYLATED-IFN AND BASELINE IMMUNOSUPPRESSION. Journal of Hepatology, 2011, 54, S323-S324.	1.8	0
202	195 LONG-TERM OUTCOME OF LIVER TRANSPLANTATION FOR HEPATITIS B WITH ANTI-HBC POSITIVE GRAFTS. Journal of Hepatology, 2012, 56, S83-S84.	1.8	0
203	236 SEXUAL DYSFUNCTION IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION. Journal of Hepatology, 2013, 58, S101-S102.	1.8	0
204	184 PREDICTIVE FACTORS OF SURVIVAL AND PROGNOSTIC SCORE VALIDATION IN LIVER RETRANSPLANTATION FOR SEVERE HEPATITIS C RECURRENCE: THE IMPORTANCE OF HCV THERAPY BEFORE AND AFTER RETRANSPLANTATION. Journal of Hepatology, 2013, 58, S81.	1.8	0
205	915 WORSE TOLERABILITY OF TRIPLE THERAPY IN SPECIAL POPULATIONS: CIRRHOTICS AND LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2013, 58, S377.	1.8	0
206	1225 TOLERABILITY TO ANTIVIRAL DUAL AND TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2013, 58, S497.	1.8	0
207	P903 CONTROL OF DIABETES MELLITUS (DM) IN LIVER TRANSPLANT RECIPIENTS (LTR). Journal of Hepatology, 2014, 60, S375-S376.	1.8	0
208	O17 IMPACT OF ANTICOAGULANT THERAPY ON UPPER GASTROINTESTINAL BLEEDING (UGI) IN PATIENTS WITH LIVER CIRRHOSIS. RESULTS FROM A RETROSPECTIVE MULTICENTRIC CASE-CONTROL STUDY. Journal of Hepatology, 2014, 60, S8.	1.8	0
209	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2014, 60, S378.	1.8	0
210	P1143 APPLICABILITY OF TRIPLE THERAPY IN CIRRHOTIC POPULATION: VALIDATION OF CUPIC DATA. Journal of Hepatology, 2014, 60, S463.	1.8	0
211	P894 PROPHYLAXIS OF DE NOVO HEPATITIS B VIRUS INFECTION WITH LAMIVUDINE IN HBsAg-NEGATIVE NAIVE RECIPIENTS OF HEPATITIS B CORE ANTIBODY-POSITIVE LIVERS: A 13-YEAR SINGLE-CENTER EXPERIENCE. Journal of Hepatology, 2014, 60, S372.	1.8	0
212	P0061 : Treatment with new all-oral direct acting antivirals in HCV-recurrence in liver transplant-setting induces a reduction of immunosuppressive drug levels. Journal of Hepatology, 2015, 62, S315.	1.8	0
213	Transplantation for Hepatitis C. , 2015, , 131-152.		0
214	Peri-Transplant Treatment with Direct-Acting Antivirals of HIV-HCV Coinfected Patients. Journal of Hepatology, 2016, 64, S552.	1.8	0
215	Liver Websites. Transplantation, 2016, 100, 1594.	0.5	0
216	The Era of the New Centurion: Long Term Outcomes of the Octogenarian Liver. Gastroenterology, 2017, 152, S1079.	0.6	0

#	ARTICLE	IF	CITATIONS
217	HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment. Journal of Hepatology, 2017, 66, S574.	1.8	0
218	Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Eradication. Transplantation, 2018, 102, S3.	0.5	0
219	The Authors' Reply: Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. Transplantation, 2020, 104, e115-e116.	0.5	0
220	Fat, cancer, the gut-liver axis and rare liver diseases. JHEP Reports, 2020, 2, 100189.	2.6	0
221	Emerging Management of Hepatitis C in Transplant. , 2021, , 951-969.		0
222	Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. Journal of Liver Transplantation, 2021, 1, 100005.	0.2	0
223	HCV Recurrence: Predictors and Outcomes After Liver Transplantation. , 2016, , 35-54.		0
224	Emerging Management of Hepatitis C in Transplant. , 2020, , 1-20.		0
225	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-86.	0.6	0
226	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 322-323.	0.6	0